- 1 Pre-COVID-19 ex vivo cross-reactive IFN-γ cellular response to SARS-CoV-2 spike
- 2 overlapping peptides is more robust among Kenyan compared to Swedish adults
- **Running Title**: Pre-COVID-19 cross-reactive IFN-γ responses to SARS-CoV-2 spike:
- 4 Kenyan vs. Swedish adults
- 5 Authors
- 6 Perpetual Wanjiku<sup>1</sup>\*, Benedict Orindi<sup>1</sup>, Jedidah Mwacharo<sup>1</sup>, James Chemweno<sup>1</sup>, Henry
- 7 Karanja<sup>1</sup>, Barbara Kronsteiner<sup>2,3</sup> Oscar Kai<sup>1</sup>, Daniel Wright<sup>4</sup>, Lynette Isabella Ochola-
- 8 Oyier<sup>1,5</sup>, Christopher Sundling<sup>6,7</sup>, Susanna Dunachie<sup>2,3</sup>, George M Warimwe<sup>1,5</sup>, Anna
- 9 Färnert<sup>6,7</sup>, Philip Bejon<sup>1,8</sup>, Francis M. Ndungu<sup>1,5,6†</sup>, Eunice Nduati<sup>1,5†</sup>.

## 10 Affiliations

- 1. Centre for Geographic Medicine Research (Coast), Kenya Medical Research Institute
- 12 (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya
- 2. Centre for Global Health Research, Nuffield Department of Medicine, University of
- 14 Oxford, Oxford, United Kingdom
- 15 3. Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Thailand
- 4. Department of Pediatrics, University of Oxford, Oxford, United Kingdom
- 5. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,
- 18 University of Oxford, Oxford, United Kingdom
- 6. Division of Infectious Diseases, Department of Medicine Solna, and Center for
- 20 Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
- 7. Department of Infectious Diseases, Karolinska University Hospital, Stockholm,
- 22 Sweden
- 8. Modernising Medical Microbiology, Nuffield Department of Medicine, University of
- 24 Oxford, Oxford, United Kingdom
- 25 \* Correspondence to: pwanjiku@kemri-wellcome.org
- †These authors contributed equally.
- 27 Highlights
- Higher frequencies of cross-reactive IFN-γ-secreting cells among Kenyan pre-
- 29 COVID-19 adults compared to Sweden.
- Trends of higher TNF-α and IFN-γ T-cell responses among Kenyan adults.
- Presence of pre-existing T-cell immunity in Sub-Saharan Africa.

32 Abstract 33 Introduction 34 Global WHO data indicate that Sub-Saharan African (SSA) countries, such as Kenya, 35 experienced reduced coronavirus disease 2019 (COVID-19) severe-morbidity and mortality 36 burdens relative to their more affluent counterparts in Europe, Asia, and North America. 37 Methods 38 We analysed peripheral blood mononuclear cells (PBMC) samples collected from Kenya and 39 Sweden before and during COVID-19. Pre-COVID-19 samples were available for 80 adults 40 and 10 infants from Kenya, and 20 adults from Sweden. COVID-19 samples were available 41 for 39 Kenyan adults. The samples were analysed for ex vivo IFN-γ secretion using an 42 Enzyme-Linked Immunosorbent (ELISpot) assay following in vitro stimulations with 43 overlapping SARS-CoV-2 spike-protein peptides. T-cells expressing IFN-γ, IL-2, TNF-α, 44 CD154, and CD107a were assessed following similar stimulations, using intracellular 45 cytokine staining (ICS) and multiparameter flow cytometry. 46 Results 47 55.7% of the Kenyan pre-COVID-19 adults were classified as responders by ELISPOT 48 responses to spike-protein peptides, compared with 28% of Swedish pre-COVID-19 adults (p. 49 = 0.04). The frequencies for SARS-CoV-2 spike-specific TNF- $\alpha$  CD4+, TNF- $\alpha$  CD8+ and 50 IFN-γ CD8+ T-cell responses, tended to be higher in the Kenyan adults although these 51 differences did not reach statistical significance. 52 Conclusion 53 Pre-COVID-19 T-cell responses could contribute to lower morbidity and mortality associated 54 with SARS-CoV-2 infections in SSA relative to Europe, Asia, and North America. 55 **Keywords:** COVID-19, SARS-CoV-2, cross-reactive responses, pre-pandemic, IFN-γ-56 secreting cells, T-cells and Sub-Saharan Africa

## Introduction

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

Most SARS-CoV-2 infections result in either asymptomatic or mild disease, but a small proportion of individuals develop severe COVID-19 requiring hospitalisation, and some of these cases result in death (1). Compared to North America, Asia and Europe, SSA experienced relatively fewer severe cases and fatalities despite many reports of similar SARS-CoV-2-infection rates (2). This paradoxical observation has puzzled many public health experts (3-5). The suggested hypotheses for the reduced burden of severe and fatal COVID-19 in SSA include potential underreporting of cases and deaths, a relatively younger population, warmer climatic conditions, and immune regulation induced from either BCG vaccinations (6–8) or previous exposures to highly inflammatory diseases like malaria (9), or cross protection from a higher level of exposure to other coronaviruses (10–16). There is evidence for cellular and humoral cross-reactivity to SARS-CoV-2 (10–16), and the role for pre-existing hCoV reactive CD4+ T-cell responses in providing SARS-CoV-2 cross protection (17). A high incidence of exposures to hCoVs and other pathogens could have induced pre-COVID-19 cross protective T-cell responses, or could have downregulated inflammation after infections of SSA residents with SARS-CoV-2 (11–16). SARS-CoV-2 cross neutralising antibodies are undetectable, even in recent confirmed cases of hCoV (18). However, antigen-specific memory T-cells are more durable and frequently cross-reactive, and may play a key role in the clearance of SARS-CoV-2 infected cells (13,19,20). Recent studies, predominantly conducted in high-income countries (HICs), have reported the presence of pre-COVID-19 cross-reactive T-cell immune responses to SARS-CoV-2 with endemic hCoVs (11–15,20). Studies from SSA countries like Uganda (21,22), Senegal (23), and South Africa (24) have provided some evidence regarding pre-COVID-19 cross-reactive T-cell to SARS-CoV-2 in adults.

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

This study examined ex vivo pre-COVID-19 IFN-γ cellular responses using ELISpot assay and the frequency of functional T-cells, expressing either IFN-γ, IL-2, TNF-α, CD154, and CD107a by multiparametric flow cytometry following in vitro stimulation with overlapping SARS-CoV-2 spike peptides. Importantly, we compared results from PBMC samples collected before 2019 from Kenyan and Swedish adults, undertaking standardised assays as a single batch in the same laboratory in Kenya. We further included additional control samples from 10 Kenyan infants (<1 year) and 39 adults COVID-19 patients. Methodology Study design and participants Kenyan pre-COVID-19 blood samples were collected from 80 adults and 10 infants aged below 1 year during an annual malaria surveillance cross-sectional survey conducted in March 2018 in Kilifi. The Swedish pre-COVID-19 blood samples had been collected from 20 healthy adult volunteers living in Sweden between March 2012 and June 2019. At the time of pre-COVID-19 sampling, all the individuals had no symptomatic or acute infection. Post-COVID-19 positive control samples were collected from 39 Kenyan adults for studies investigating the kinetics of the immune response to SARS-CoV-2 in COVID-19 patients in Kilifi and Nairobi between 1<sup>st</sup> August 2020 and 15<sup>th</sup> February 2022. Blood was separated into plasma and PBMCs and stored at -80°C and liquid nitrogen, respectively, until used for analyses. All the participants consented for their respective samples to be used for both the contemporaneous and future research. This project received ethical approval from the Kenya Medical Research Institute's (KEMRI) Scientific and Ethics Review Unit (SERU) under protocols SERU 3149, 4081 and 4085. Ethical approval for the collection of the Swedish samples was obtained from the regional Ethics Committee in Stockholm, Sweden under protocols 2006/893-31/4 and 2019-03436.

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

Overlapping SARS-CoV-2 spike peptides and in vitro stimulants for PBMC in the **ELISpot** assay Pools of peptides covering the spike region 1 (S1) and spike region 2 (S2) of the SARS-CoV-2 spike protein were synthesised by Mimotopes Pty Ltd. Each peptide was 15-mers long and overlapped with the next by 10 amino acid residues. A total of 12 mini-pools, P1 to P12 (Proimmune), which corresponded to SARS-CoV-2 spike regions S1 (P1 to P6) and S2 (P7 to P12) (25) were used. Two positive controls, phytohemagglutinin-L (PHA-L, Sigma) and anti-CD3, were used to induce a mitogenic response and demonstrate viability of lymphocytes and T-cells, respectively. A negative control (i.e., no peptide but with the Dimethyl sulfoxide [DMSO] carrier) was also included to detect non-specific IFN-γ release. The first 10 samples with sufficient cell numbers to test against all 12 peptide pools were included in a preliminary analysis to guide peptide pool prioritisation when participant's PBMCs recovered after thawing yielded insufficient numbers for testing across all pools. Following this analysis, 4 peptide pools, 3 and 4 representing S1 region, and 8 and 10 representing S2 region, were prioritised when the numbers of PBMCs were inadequate (Figure S1). **ELISpot** assay We used an IFN-γ ELISpot assay, which quantifies the frequency of antigen-specific effector cells producing IFN-y after an overnight co-culture of PBMC with either specific peptides or a non-antigen specific positive control (25). Briefly, 96 well ELISpot plates (Millipore, UK) were coated with a monoclonal antibody against IFN-γ (Mabtech, AB, Sweden) at 10μg/mL overnight. 200000 PBMCs per well were plated in triplicates for each individual and plates incubated at 37°C in a humidified carbon dioxide (5%) incubator for 16–18 hours of stimulation with overlapping peptide pools at 10µg/mL in triplicate wells. After incubation,

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

PBMCs were discarded, the plate washed, and the detector for the secreted IFN-γ footprints on the plate membrane, anti- IFN-γ biotinylated monoclonal antibody (Mabtech), added at lug/mL and the plate incubated for 2 hours at room temperature. The plate was then washed, and streptavidin alkaline phosphatase (Mabtech) added at 1µg/mL, before another incubation for 1 hour at room temperature. Following washing, the 1-StepTM NBT/BCI (nitro blue tetrazolium/5-bromo-4-chloro-3-phosphatase) substrate (Thermo Scientific) was added, and the plate left in the dark for 7 minutes until the developing spots were clearly visible. The plate was then washed three times using tap water. Following overnight drying, the spots in each well were enumerated with an AID ELISpot Reader (v.4.0). Counts were presented as IFN-γ Spot-Forming Units (SFUs) per million PBMC, which is determined by taking an average of the triplicate wells. Results are reported here as SFUs per million PBMCs after subtracting the background (mean of individual negative wells) from the antigen-specific responses. We summed up the responses from pools P3 and P4 (representing S1) and pools P8 and P10 (representing S2). For the spike region, we combined the aggregated responses from S1 and S2. Individual's assays were considered failed, and their results excluded if the negative control wells had >150 SFUs per million PBMCs, or the positive control wells had <200 SFUs per million PBMCs. An ELISpot assay limit of detection of 10 SFUs per million PBMCs was also applied, and all wells with values <10 SFUs per million PBMCs replaced with a possible minimal result equal to 5 SFUs per million PBMCs. Individuals' IFN-γ cellular responses were considered positive, if their SFUs were >71 SFUs per million PBMCs after background subtraction (corresponding to the 25<sup>th</sup> percentile of Kenyan COVID-19 patients). In total, 79 of 80 pre-COVID-19 Kenyan adults, 10 of 10 of the Kenyan infants, 18 of 20 Swedish adults and 37 of 39 post-COVID-19 Kenyan adult patients diagnosed with COVID-19 were included in the analysis. Of participants included in the analysis, 78 (99%) pre-

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

COVID-19 Kenyan adults, 3 (30%) Kenyan infants, 5 (28%) Swedish adults and 14 (38%) COVID positive Kenyan patients had all the 12 peptide pools tested (Table S1). Due to the small number of infants, Swedish adults and COVID cases with entire 12 peptide pools tested, subsequent analyses were restricted to the prioritised pools 3 and 4 for S1 responses and pools 8 and 10 for S2 responses, and a summation of pools 3, 4, 8 and 10 for total spike responses (Figure S1). Synthetic peptide pools for intracellular cytokine staining stimulation assay A total of 178 peptides (15–18-mers with a ten amino acid overlap) spanning the entire SARS-CoV-2 spike protein (S: positions 1–178) were synthesised by Mimotopes Pty Ltd and pooled together into one pool for PBMC stimulations. DMSO was used as a negative control and PMA/ionomycin as a positive control. Intracellular cytokine staining and multi-parametric flow cytometry To determine T-cell function, we used ICS and multiparametric flow cytometry to identify and quantify effector T-cells responding to *in vitro* stimulation by overlapping SARS-CoV-2 spike peptides with IL-2, IFN- $\gamma$  and TNF- $\alpha$  cytokine secretion, and upregulation of CD154 and CD107a activation makers. Briefly, cryopreserved PBMCs were thawed and rested for 2-4 hours and thereafter plated at  $1 \times 10^6$  live cells per well for SARS-CoV-2 spike peptide stimulations and the DMSO, and at  $0.5 \times 10^6$  live cells per well for PMA/ionomycin in 96well round-bottom plates. SARS-CoV-2 spike peptide stimulation was done at a final concentration of 2 µg/mL, PMA at 0.05 µg/mL and ionomycin (Sigma) at 0.5 µg/mL, and DMSO (Sigma) at 2 µg/mL. All the stimulations and controls were done in the presence of the co-stimulatory anti-CD28 and anti-CD49 (1 µg/mL, BD Biosciences) antibodies. CD107a BV421 (0.04 μg/ml, BD Biosciences) was added to all wells and cells incubated for 1 hour at

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

37°C temperature, 5% CO<sub>2</sub>, 95% humidity for surface staining. Following incubation, Brefeldin A (5 µg/mL, MP Biomedicals) was added, and cells incubated for a further 15 hours. After washing the cells with 1X PBS, dead cells were labelled using live/dead fixable aqua dye (Invitrogen) for 30 mins at 25°C. The cells were then washed with 1X Perm/Wash before fixation and permeabilisation using Cytofix-Cytoperm for 20 mins at 4°C. Cells were washed three times with 1X Perm/Wash and then stained with APC 'Fire' 750 anti- CD3 (Biolegend), PE Dazzle 594-anti- CD4 (Biolegend), PercpCy5.5-anti- CD8 (Biolegend), PECy7- anti-CD154 (Biolegend), APC-anti- IFN-γ (BD Biosciences), PE-anti- IL2 (Biolegend) and FITC-anti- TNF-α (BD Biosciences) for 20 mins at 4°C. Cells were washed twice with 1X Perm/Wash and resuspended in 200 µl 1X PBS and stored at 4°C in the dark until acquisition. Samples were acquired on a BD LSR Fortessa (BD Biosciences) flow cytometer, and data analysed using FlowJo version 10.10.0 software. Gating strategies used are detailed in (Figure S2). Results are presented as the proportion of IFN-γ, IL-2 or TNF-α secreting CD4 or CD8 T-cells, or as the proportion of CD154 expressing CD4 T-cells or CD107a expressing CD8 T-cells after subtracting the background (values from negative control wells for each sample). A limit of detection of 0.02% was applied, and all wells with values below 0.02% were replaced with the lowest possible value of 0.01%. Boolean gates were used to examine the frequency of polyfunctional T-cells defined as CD4 or CD8 T-cells co-expressing any of the cytokines IFN-γ, TNF-α, IL-2 and surface markers CD154 or CD107a. Statistical analysis Data management and statistical analysis were performed using GraphPad Prism version 10.2.3 (26). IFN-γ SFUs detected by ELISPOT were log-transformed prior to analysis. For the primary analysis, pairwise comparisons were performed between Kilifi pre-COVID-19

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

adults and Swedish pre-COVID-19 adults to assess differences in IFN-γ SFUs, as well as the proportions of cytokine secreting T-cells and T-cell activation markers in response to SARS-CoV-2 spike peptides or its subregions (S1 or S2). A two-sample t-test was used to compare IFN-γ SFUs as continuous variables, while Fisher's exact test was applied to compare the proportions of responders to SARS-CoV-2 spike peptides between Kilifi pre-COVID-19 adults and Swedish pre-COVID-19 adults. The Mann Whitney test was used for comparisons of the proportions of cytokine-secreting T-cells and T-cell activation markers. For the secondary analysis, a one-way analysis of variance (ANOVA) with Tukey's multiple comparisons test was used to evaluate differences in IFN-γ SFUs across all four study groups. The Kruskal Wallis test with Dunn's multiple comparisons test was used to compare the proportions of cytokine secreting T-cells and T-cell activation markers in response to SARS-CoV-2 spike peptides or subregions across the study groups. A paired t-test was used to assess interindividual variability in responses to peptides corresponding to S1 and S2. All tests were performed at 5% significance level. Results **Participants characteristics** The median ages of the pre-COVID-19 study participants were 31 years (IQR 24-40 – for Kenyan adults, 33 years (IQR 31-41) for Swedish adults, and 0.75 years (IQR 0.58-0.83) for Kenyan infants. The proportions of male participants were 29% for Kenya adults, 5% for Swedish adults and 50% for Kenyan infants. Kenyan COVID-19 patients had a median age of 43 years (IQR 34-55), with about one in two being male (Table S2). IFN-γ responses by ELISpot For the S1 region, Kenyan pre-COVID-19 adults tended to have higher IFN-γ responses (with a geometric mean of 42 [95% CI 31–56] SFUs per million PBMCs) than Swedish pre-

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

COVID adults (geometric mean of 22 [95% CI 12–39] SFUs per million PBMCs; p = 0.05). For the S2 region, Kenyan and Swedish pre-COVID-19 adults had similar geometric mean responding T-cell numbers at geometric mean of 24 (95% CI: 19–30) and 27 (95% CI: 16– 45), SFUs per million PBMCs, respectively (p = 0.66; Figure 1a). With S1 and S2 regions combined, Kenyan pre-COVID-19 adults had higher responses (geometric mean of 70 [95% CI 53–93]) than Swedish pre-COVID-19 adults (49 [95% CI 29–84]; p = 0.26; Figure 1b). Amongst the Kilifi pre-COVID-19 adults there were higher S1 responses compared to S2 responses (geometric mean of 42 [95% CI 31–56] vs. 24 [95% CI 19–30] SFUs per million PBMCs; p < 0.0001) (Figure S3a). For the Swedish pre-COVID-19 and infants pre-COVID-19, the magnitude of S1 and S2 responses were similar (Figures S3ac). We next analysed the proportion of responders within each subgroup. Responders were defined as individuals with IFN-γ SFUs responses exceeding 71 SFU per million PBMCs after background subtraction, corresponding to the 25th percentile of Kenyan COVID-19 patients. Notably, 55.7% of the Kenyan pre-COVID-19 adults were classified as responders, which was significantly higher than 28% of Swedish pre-COVID-19 adults (p = 0.04) in response to SARS-CoV-2 spike peptides. Among Kenyan pre-COVID-19 infants, 40% were responders. As expected, a large proportion, 75.7% of the COVID-19 positive individuals were classified as responders (Figure 1c). Cross reactive cytokine responses to SARS-CoV-2 peptides by ICS To establish whether the IFN-γ responses observed by ELISpot were from memory T-cells and whether other cytokines were secreted, we incorporated ICS assay followed by multiparametric flow cytometry. Our data show that both CD4+ and CD8+ T-cells from the different groups produced IFN-γ, TNF-α and IL-2 after incubation with overlapping SARS-

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

CoV-2 spike peptides. CD4+ T-cells also upregulated CD154 an activation marker. Kenyan pre-COVID-19 adults exhibited higher cytokines levels for IFN-γ and TNF-α responses, though not statistically significant (Figure 2). For the IFN-γ CD8+ T-cell responses, Kenyan pre-COVID-19 adults had a higher median of 0.06% (IQR 0.01–0.54%) compared to Swedish pre-COVID-19 adults (median: 0.01% [IQR 0.01-0.4%]; p = 0.54). The TNF- $\alpha$ CD4+ T-cell responses were higher in Kenyan pre-COVID-19 adults (median: 0.03% [IQR 0.01–0.095%]) than Swedish pre-COVID-19 adults (median: 0.015% [IQR 0.01–0.055%]; p = 0.39). Similarly, TNF-α CD8+ T-cell responses were elevated in Kenyan pre-COVID-19 adults (median: 0.06% [IOR 0.01–0.17%]) compared to Swedish pre-COVID-19 adults (median: 0.03% [IQR 0.01-0.05%]; p = 0.13) (Figure 2b, c-d). The Kenyan COVID-19 patients had significantly higher TNF-α CD4+ T-cells levels (median: 0.26% [IQR 0.11– 0.73%]) compared to Kenyan pre-COVID-19 adults, (median: 0.03% [IQR 0.01–0.095%]; p=0.01), Kenyan pre-COVID-19 infants (median: 0.02% [IQR 0.01–0.04%]; p= 0.007) and Swedish pre-COVID-19 adults (median: 0.015% [IQR 0.01–0.055%]; p= 0.005) (Figure 2c). IL-2 CD4+ T-cell frequencies were also higher in Kenyan COVID-19 patients (median: 0.09% [IQR 0.015–0.515%]) compared to Kenyan pre-COVID-19 adults (median: 0.01% [IQR 0.01–0.025%]; p= 0.02) and Swedish pre-COVID-19 adults (median: 0.01% [IQR 0.01-0.01%]; p= 0.004) (Figure 2e). Our analysis of the number of functional markers co-expressed by these T-cells showed that only a small proportion of individuals showed polyfunctionality prior to COVID-19. Individuals analysed post COVID-19 had better CD4 and CD8 T-cell polyfunctionality. Compared to Swedish pre-COVID-19 adults, a higher proportion of Kenyan pre-COVID-19 adults had polyfunctional CD4+ and CD8+ T-cells (Figure S4a, b). Collectively, these data suggest that the pre-COVID-19 CD4+ and CD8+T-cells from Swedish adults were less primed to secrete TNF- $\alpha$  and IFN- $\gamma$  compared to those of the Kenyan pre-COVID-19 adults.

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

## **Discussion** We compared the frequencies and prevalence of SARS-CoV-2 cross-reactive T-cell responses by measuring IFN-γ responses by ELISPOT and phenotypic and functional characterization by flow cytometry in pre-COVID-19 PBMC collected in Kenya, and in Sweden. We observed higher S1 specific and full spike frequencies, and a greater prevalence, of pre-pandemic SARS-CoV-2 spike peptide specific cross-reactive IFN-γ secreting cells measured by an ELISpot assay in Kenyan adults, compared to Swedish adults. Overall, these data suggest that Kenyan pre-COVID-19 adults had higher IFN-γ SFU responses to the S1 and spike regions but similar S2 responses compared to Swedish pre-COVID-19 adults. A larger proportion of Kenyan pre-COVID-19 adults also responded to SARS-CoV-2 spike peptides. Responses to S1-specific S2-specific, and to the full spike region increased following contact with COVID-19. These findings suggest a greater pre-pandemic exposure to S1-like epitopes in Kenya contributing to SARS-CoV-2 cross-reactive T-cell responses compared to Sweden. We confirmed, using ICS assay, that the spike-peptide specific IFN-γ secreting cells included both CD4+ and CD8+ T-cells. Furthermore, we did not identify evidence that the Kenyan pre-COVID-19 adults had statistically significantly higher frequencies of pre-pandemic SARS-CoV-2 spike-specific TNF-α, or IFN-γ responses either in CD4+ T-cell responses or CD8+ T-cell responses compared to their Swedish counterparts. However, the ELISPOT assay is more sensitive than the ICS assay we used, and therefore the power to detect differences between populations is more limited in the ICS work. The higher frequencies and prevalence of IFN-γ secreting cells among the Kenyan prepandemic adult-PBMCs compared to their Swedish counterparts is consistent with higher levels of pre-existing anti-SARS-CoV-2 cross protective immunity in SSA. These higher frequencies of pre-pandemic SARS-CoV-2 cross reactive cells may contribute to the lower

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

prevalence of severe COVID-19 and deaths in Kenya relative to European countries like Sweden. This idea is consistent with previous observations of protection from severe COVID-19 by recent exposures to endemic hCoVs (27). Furthermore, mechanistic studies in mice demonstrated that hCoV-specific, SARS-CoV-2-cross-reactive T -cells contribute to SARS-CoV-2 immune responses upon infection and vaccination (17). There is little evidence for a role for cross-reactive neutralising antibodies as these are rare, even where there is PCR evidence for recent hCoV infection (18). The mechanism by which SARS-CoV-2 cross reactive CD4+ T-cells lower COVID-19 severity may include various mechanisms such as the direct killing of virus infected cells, or through their ability to offer CD8 T cells help and protecting against infection, or both, thus reducing viral loads (28–30). Alternatively (or in addition), SARS-CoV-2 cross reactive memory CD4+ T-cells may provide the necessary costimulatory molecules for helping rapid and amnestic production of protective antibodies (17). This study has a few limitations. First, for the ICS assays, we only had access to PBMC from 21 Kenyan pre-covid-19 adults, 10 Kenyan pre-covid-19 infants, 10 Swedish pre-covid-19 adults and 9 Kenyan covid-19 adults, which reduced the statistical power of comparing responses among the groups. Second, we were only able to use spike peptides to stimulate PBMCs as the numbers of cells was limiting, it would have been more comprehensive to include other SARS-CoV-2 proteins. Conclusion We report higher frequencies and prevalence of pre-COVID-19 SARS-CoV-2 spike crossreactive IFN- γ secreting cells, some of which include CD8+ T -cells, among Kenyan compared to Swedish adults. This raises the possibility that higher levels of cross-protective cellular responses in SSA could explain, at least in part, why there was less severe morbidity

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

and mortality on the continent relative to Europe, Asia and North America. Nonetheless, subsequent studies including relatively higher samples sizes of pre-COVID-19 PBMC from SSA and a few more countries from Europe and/or America are required to confirm these findings and extend the research into investigating the actual mechanism of the SARS-CoV-2 cross-protection. Importantly, such studies will provide new insights on how to develop novel cross-protective vaccines against similar pathogens, like coronaviruses. Acknowledgments We thank the field workers, laboratory staff and healthcare workers involved in the blood sampling. We appreciate all the study participants. **Competing Interests** No competing interests to declare. **Funding Statement** This study/project is funded by the EDCTP2 Programme (grant number RIA2020EF-3042) which is supported by the European Union, and the Swedish International Development Cooperation Agency. SJD is supported by an NIHR Global Health Research Professorship (NIHR300791). References 1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 □ 314 Cases

- From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr
- **356** 7;323(13):1239–42.
- 2. Cabore JW, Karamagi HC, Kipruto HK, Mungatu JK, Asamani JA, Droti B, et al.
- 358 COVID-19 in the 47 countries of the WHO African region: a modelling analysis of past
- trends and future patterns. Lancet Glob Health. 2022 Aug;10(8):e1099–114.
- 360 3. Osayomi T, Adeleke R, Akpoterai LE, Fatayo OC, Ayanda JT, Moyin-Jesu J, et al. A
- Geographical Analysis of the African COVID-19 Paradox: Putting the Poverty-as-a-
- Vaccine Hypothesis to the Test. Earth Syst Environ. 2021 Sep 1;5(3):799–810.
- 363 4. Ghosh D, Bernstein JA, Mersha TB. COVID-19 pandemic: The African paradox. J Glob
- 364 Health. 10(2):020348.
- 365 5. Maeda JM, Nkengasong JN. The puzzle of the COVID-19 pandemic in Africa. Science.
- 366 2021 Jan;371(6524):27–8.
- 367 6. Wamai RG, Hirsch JL, Van Damme W, Alnwick D, Bailey RC, Hodgins S, et al. What
- 368 Could Explain the Lower COVID-19 Burden in Africa despite Considerable Circulation
- of the SARS-CoV-2 Virus? Int J Environ Res Public Health. 2021 Aug 16;18(16):8638.
- 370 7. Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe
- 371 coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci U S A. 2020 Jul
- 372 28;117(30):17720-6.
- 373 8. Gonzalez-Perez M, Sanchez-Tarjuelo R, Shor B, Nistal-Villan E, Ochando J. The BCG
- 374 Vaccine for COVID-19: First Verdict and Future Directions. Front Immunol. 2021 Mar
- **375** 8;12:632478.
- 376 9. Tapela K, Prah DA, Tetteh B, Nuokpem F, Dosoo D, Coker A, et al. Cellular immune
- 377 response to SARS-CoV-2 and clinical presentation in individuals exposed to endemic
- 378 malaria. Cell Reports. 2024 Aug 27;43(8):114533.

- 379 10. Ashworth J, Mathie D, Scott F, Mahendran Y, Woolhouse M, Stoevesandt O, et al.
- Peptide microarray IgM and IgG screening of pre-SARS-CoV-2 human serum samples
- from Zimbabwe for reactivity with peptides from all seven human coronaviruses: a cross-
- sectional study. The Lancet Microbe. 2023 Apr 1;4(4):e215–27.
- 383 11. Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-
- reactive T -cells in healthy donors and patients with COVID-19. Nature. 2020 Nov
- **385** 12;587(7833):270–4.
- 386 12. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-
- specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.
- 388 Nature. 2020 Aug;584(7821):457–62.
- 389 13. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets
- of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease
- and Unexposed Individuals. Cell. 2020 Jun 25;181(7):1489-1501.e15.
- 392 14. Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, et al.
- 393 Phenotype and kinetics of SARS-CoV-2–specific T -cells in COVID-19 patients with
- acute respiratory distress syndrome. Science Immunology. 2020 Jun 26:5(48):eabd2071.
- 395 15. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and cross-
- reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020 Oct
- 397 2;370(6512):89–94.
- 398 16. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021
- 399 Feb;184(4):861–80.
- 400 17. Loyal L, Braun J, Henze L, Kruse B, Dingeldey M, Reimer U, et al. Cross-reactive CD4+
- T -cells enhance SARS-CoV-2 immune responses upon infection and vaccination.
- 402 Science. 2021 Oct 8;374(6564):eabh1823.

- 403 18. Poston D, Weisblum Y, Wise H, Templeton K, Jenks S, Hatziioannou T, et al. Absence
- of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in
- 405 Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection. Clin
- 406 Infect Dis. 2021 Sep 7;73(5):e1208–11.
- 407 19. de Candia P, Prattichizzo F, Garavelli S, Matarese G. T -cells: Warriors of SARS-CoV-2
- 408 Infection. Trends Immunol. 2021 Jan;42(1):18–30.
- 409 20. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al.
- 410 Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild
- 411 COVID-19. Cell. 2020 Oct 1;183(1):158-168.e14.
- 412 21. Namuniina A, Muyanja ES, Biribawa VM, Okech BA, Ssemaganda A, Price MA, et al.
- Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and
- 414 CD8+ T-cell responses: A pilot study. PLOS Global Public Health. 2023 Aug
- 415 16;3(8):e0001566.
- 416 22. Nantambi H, Sembera J, Ankunda V, Ssali I, Kalyebi AW, Oluka GK, et al. Pre-
- pandemic SARS-CoV-2-specific IFN-γ and antibody responses were low in Ugandan
- samples and significantly reduced in HIV-positive specimens. Front Immunol [Internet].
- 419 2023 Apr 19 [cited 2024 Sep 23];14. Available from:
- 420 https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1148877/
- 421 full
- 422 23. Herrera BB, Chaplin B, MBoup S, Abdullahi A, He M, Fisher SM, et al. West African
- pre-pandemic cross-reactive antibody and cellular responses against SARS-CoV-2
- 424 [Internet]. medRxiv; 2024 [cited 2024 Sep 23]. p. 2024.05.21.24307417. Available from:
- 425 https://www.medrxiv.org/content/10.1101/2024.05.21.24307417v1
- 426 24. Nunes MC, Johnson MJ, Kwatra G, Weinberg A, Madhi SA. T-cell responses to SARS-
- 427 CoV-2 in unexposed South African women. Gates Open Res. 2022 Jul 13;5:150.

- 428 25. Ogbe A, Kronsteiner B, Skelly DT, Pace M, Brown A, Adland E, et al. T cell assays
- differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral
- 430 responses. Nat Commun. 2021 Apr 6;12(1):2055.
- 431 26. Graph pad prism programming team. Graph pad Prism, Boston, Massachusetts, USA.
- 432 2023 [cited 2024 Apr 11]. Prism GraphPad. Available from:
- 433 https://www.graphpad.com/features
- 434 27. Sagar M, Reifler K, Rossi M, Miller NS, Sinha P, White LF, et al. Recent endemic
- coronavirus infection is associated with less-severe COVID-19. J Clin Invest [Internet].
- 436 2021 Jan 4 [cited 2024 Oct 30];131(1). Available from:
- https://www.jci.org/articles/view/143380
- 438 28. Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022
- 439 Feb;23(2):186–93.
- 440 29. Wyllie D, Jones HE, Mulchandani R, Trickey A, Taylor-Phillips S, Brooks T, et al.
- 441 SARS-CoV-2 responsive T cell numbers and anti-Spike IgG levels are both associated
- with protection from COVID-19: A prospective cohort study in keyworkers [Internet].
- 443 medRxiv; 2021 [cited 2024 Sep 20]. p. 2020.11.02.20222778. Available from:
- 444 https://www.medrxiv.org/content/10.1101/2020.11.02.20222778v2
- 445 30. Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, et al. Cross-reactive
- 446 memory T -cells associate with protection against SARS-CoV-2 infection in COVID-19
- 447 contacts. Nat Commun. 2022 Jan 10;13(1):80.
- 449 Figures

- 450 Figure 1. Comparison of the frequencies of IFN-gamma secreting cell responses to
- 451 SARS-CoV-2 Spike regions 1 and 2 among study groups. a frequencies of Spike regions 1
- and 2 separately, **b** aggregated frequencies of Spike regions 1 and 2, **c** Responders (Cut off

for responders is 25<sup>th</sup> percentile of Spike in CoV-adults). Comparisons done using t-test, ordinary one-way ANOVA with Tukey's multiple comparisons test and Fisher's exact test.

Black line shows Geometric mean.




Figure 2. Proportions of T cells expressing cytokines and surface markers in response to SARS-CoV-2 Spike protein. i) Cytokine responses levels of a IFN-γ in CD4+ T cells, b IFN-γ in CD8+ T cells, c TNF in CD4+ T cells, d TNF in CD8+ T cells, e IL-2 in CD4+ T cells, f IL-2 in CD8+ T cells ii) Surface markers g CD154 on activated CD4+ T cells h CD107a on CD8+ T cells.

Number of participants for: Kilifi pre-covid adults = 21, Kilifi pre-covid infants = 11, Sweden pre-covid adults = 10, Covid-19 adults = 9. Black line shows median.

